Comparison of catalytic properties of cytochromes p450 3a4 and 3a5 by molecular docking simulation

Drug Metabolism Letters

Volumn 8, Issue 1, 2014, Pages 43-50

  Niwa, Toshiro ^a   Yasumura, Motohiro ^b   Murayama, Norie ^b   Yamazaki, Hiroshi ^b  

^a SHUJITSU UNIVERSITY   (Japan)

^b SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Accessibility; Affinity; CYP3A4; CYP3A5; Docking simulation; Metabolic activity

Indexed keywords

CAREBASTINE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; ENDOSULFAN; ESTRADIOL; FLUINDOSTATIN; HALOPERIDOL; HEME; ITRACONAZOLE; MIDAZOLAM; TRIAZOLAM; VINCRISTINE; CYP3A4 PROTEIN, HUMAN; CYP3A5 PROTEIN, HUMAN; CYTOCHROME P450 3A;

ARTICLE; CATALYSIS; COMPUTER PROGRAM; ENERGY; KINETICS; MICHAELIS CONSTANT; MOLECULAR DOCKING; OXIDATION; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THREE DIMENSIONAL IMAGING; BIOTRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; COMPARATIVE STUDY; ENZYME ACTIVE SITE; ENZYME SPECIFICITY; HUMAN; HYDROXYLATION; METABOLISM; OXIDATION REDUCTION REACTION; PROTEIN CONFORMATION;

RUMEX;

BIOTRANSFORMATION; CATALYTIC DOMAIN; CYTOCHROME P-450 CYP3A; HUMANS; HYDROXYLATION; KINETICS; MOLECULAR DOCKING SIMULATION; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROTEIN CONFORMATION; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBSTRATE SPECIFICITY;

EID: 84925387124     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1872312807666131229121228     Document Type: Article

References (26)

1. [1] Wilkinson G.R. Cytochrome P4503A (CYP3A) metabolism: prediction of in vivo activity in humans. J. Pharmacokinet. Biopharm., 1996, 24, 475-490.
2. [2] Daly, A.K. Significance of the minor cytochrome P450 3A isoforms. Clin. Pharmacokinet., 2006, 45, 13-31.
3. [3] Bu, H.Z. A literature review of enzyme kinetic parameters for CYP3A4-mediated metabolic reactions of 113 drugs in human liver microsomes: structure-kinetics relationship assessment. Current Drug Metab., 2006, 7, 231-249.
4. [4] Kuehl, P.; Zhang, J.; Lin, Y.; Lamba, J.; Assem, M.; Schuetz, J.; Watkins, P.B.; Daly, A.; Wrighton, S.A.; Hall, S.D., Maurel, P.; Relling, M.; Brimer, C.; Yasuda, K.; Venkataramanan, R.; Strom, S.; Thummel, K.; Boguski, M.S.; Schuetz, E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet., 2001, 27, 383-391.
5. [5] de Wildt, S.N.; Kearns, G.L.; Leeder, J.S.; van den Anker, J.N. Cytochrome P450 3A: ontogeny and drug disposition. Clin. Pharmacokinet., 1999, 37, 485-505.
6. [6] Niwa, T.; Murayama, N.; Emoto, C.; Yamazaki, H. Comparison of kinetic parameters for drug oxidation rates and substrate inhibition potential mediated by cytochrome P450 3A4 and 3A5. Curr. Drug Metab., 2008, 9, 20-33.
7. [7] Niwa, T.; Murayama, N.; Yamazaki, H. Comparison of the contributions of cytochrome P450 3A4 and 3A5 in drug oxidation rates and substrate inhibition. J. Health Sci., 2010, 56, 239-256.
8. [8] Okada, Y.; Murayama, N.; Yanagida, C.; Shimizu, M.; Guengerich, F.P.; Yamazaki, H. Drug interactions of thalidomide with midazolam and cyclosporine A: heterotropic cooperativity of human cytochrome P450 3A5. Drug Metab. Dispos., 2009, 37, 18-23.
9. [9] Akiyoshi, T.; Saito, T.; Murase, S.; Miyazaki, M.; Murayama, N.; Yamazaki, H.; Guengerich, F.P.; Nakamura, K.; Yamamoto, K.; Ohtani, H. Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants. Drug Metab. Dispos., 2011, 39, 724-728.
10. [10] Williams, J.A.; Ring, B.J.; Cantrell, V.E.; Jones, D.R.; Eckstein, J.; Ruterbories, K.; Hamman, M.A.; Hall, S.D.; Wrighton, S.A. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab. Dispos., 2002, 30, 883-891.
11. [11] Huang, W.; Lin, Y.S.; McConn, D.J. 2nd; Calamia, J.C.; Totah, R.A.; Isoherranen, N.; Glodowski, M.; Thummel, K.E. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab. Dispos., 2004, 32, 1434-1445.
12. [12] Patki, K.C.; Von Moltke, L.L.; Greenblatt, D.J. In vitro metabolism of midazolam, triazolam, nifedipine, and testosterone by human liver microsomes and recombinant cytochromes P450: role of CYP3A4 and CYP3A5. Drug Metab. Dispos., 2003, 31, 938-944.
13. [13] Galetin, A.; Brown, C.; Hallifax, D.; Ito, K.; Houston, J.B. Utility of recombinant enzyme kinetics in prediction of human clearance: impact of variability, CYP3A5, and CYP2C19 on CYP3A4 probe substrates. Drug Metab. Dispos., 2004, 32, 1411-1420.
14. [14] Isoherranen, N.; Ludington, S.R.; Givens, R.C.; Lamba, J.K.; Pusek, S.N.; Dees, E.C.; Blough, D.K.; Iwanaga, K.; Hawke, R.L.; Schuetz, E.G.; Watkins, P.B.; Thummel, K.E.; Paine, M.F. The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation. Drug Metab. Dispos., 2008, 36, 146-154.
15. [15] Quintieri, L.; Palatini, P.; Nassi, A.; Ruzza, P.; Floreani, M. Flavonoids diosmetin and luteolin inhibit midazolam metabolism by human liver microsomes and recombinant CYP 3A4 and CYP3A5 enzymes. Biochem. Pharmacol., 2008, 75, 1426-1437.
16. [16] Yamaori, S.; Yamazaki, H.; Suzuki, A.; Yamada, A.; Tani, H.; Kamidate, T.; Fujita, K.; Kamataki, T. Effects of cytochrome b(5) on drug oxidation activities of human cytochrome P450 (CYP) 3As: similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem. Pharmacol., 2003, 66, 2333-2340.
17. [17] Yamaori, S.; Yamazaki, H.; Iwano, S.; Kiyotani, K.; Matsumura, K.; Honda, G.; Nakagawa, K.; Ishizaki, T.; Kamataki, T. CYP3A5 contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab. Pharmacokinet., 2004, 19, 120-129.
18. [18] Liu, K.H.; Kim, M.G.; Lee, D.J.; Yoon, Y.J.; Kim, M.J.; Shon, J.H.; Choi, C.S.; Choi, Y.K.; Desta, Z.; Shin, J.G. Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A. Drug Metab. Dispos., 2006, 34, 1793-1797.
19. [19] Fischer, V.; Johanson, L.; Heitz, F.; Tullman, R.; Graham, E.; Baldeck, J.P.; Robinson, W.T. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor fluvastatin: effect on human cytochrome P-450 and implications for metabolic drug interactions. Drug Metab. Dispos., 1999, 27, 410-416.
20. [20] Kalgutkar, A.S.; Taylor, T.J.; Venkatakrishnan, K.; Isin, E.M. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway. Drug Metab. Dispos., 2003, 31, 243-249.
21. [21] Dennison, J.B.; Kulanthaivel, P.; Barbuch, RJ.; Renbarger, J.L.; Ehlhardt, W.J.; Hall, S.D. Selective metabolism of vincristine in vitro by CYP3A5. Drug Metab. Dispos., 2006, 34, 1317-1327.
22. [22] Shen, L.; Fitzloff, J.F.; Cook, C.S. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As. Drug Metab. Dispos., 2004, 32, 186-196.
23. [23] Lee, H.K.; Moon, J.K.; Chang, C.H.; Choi, H.; Park, H.W.; Park, B.S.; Lee, H.S.; Hwang, E.C.; Lee, Y.D.; Liu, K.H.; Kim, J.H. Stereoselective metabolism of endosulfan by human liver microsomes and human cytochrome P450 isoforms. Drug Metab. Dispos., 2006, 34, 1090-1095.
24. [24] Gibbs, M.A.; Thummel, K.E.; Shen, D.D.; Kunze, K.L. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression. Drug Metab. Dispos., 1999, 27, 180-187.
25. [25] Yamazaki, H.; Nakamoto, M.; Shimizu, M.; Murayama, N.; Niwa, T. Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles. Br. J. Clin. Pharmacol., 2010, 69, 593-597.
26. [26] Brüggemann, R.J.; Alffenaar, J.W.; Blijlevens, N.M.; Billaud, E.M.; Kosterink, J.G.; Verweij, P.E.; Burger, D.M. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin. Infect. Dis., 2009, 48, 1441-1458.